Loading…
Dermata Therapeutics, Inc. is projected to decline to $1.25 by 2027, a -4% move from its current price of $1.30. DRMA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.26 | $1.30 | $1.35 | +0.04% |
| May 30 | $1.24 | $1.30 | $1.37 | +0.08% |
| May 31 | $1.23 | $1.30 | $1.38 | +0.12% |
| Jun 1 | $1.21 | $1.30 | $1.40 | +0.16% |
| Jun 2 | $1.20 | $1.30 | $1.41 | +0.20% |
| Jun 3 | $1.20 | $1.30 | $1.42 | +0.24% |
| Jun 4 | $1.19 | $1.30 | $1.43 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.30 | $1.43 | +0.28% |
| Week 2 | $1.15 | $1.31 | $1.49 | +0.57% |
| Week 3 | $1.12 | $1.31 | $1.54 | +0.85% |
| Week 4 | $1.09 | $1.31 | $1.58 | +1.14% |
| Week 5 | $1.07 | $1.32 | $1.62 | +1.42% |
| Week 6 | $1.05 | $1.32 | $1.66 | +1.71% |
| Week 7 | $1.04 | $1.33 | $1.69 | +2.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. It is categorized within Healthcare.
Dermata Therapeutics, Inc., DRMA, is currently trading at $1.26.
The asset has a market capitalization of $5.07M and is ranked #5340.
Forecasts indicate an evolving price outlook across 2026 to 2050, with average prices rising from $1.26 in 2026 to $4.44 by 2050, including a 2050 max of $9.02.
A major floor 15.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.2% below — buyers have tended to step in here.
The nearest ceiling, 5.4% above — a clean break opens room to run.
A major ceiling 136.9% above — clearing it would confirm fresh momentum.
Key DRMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.26 | Buy | $1.26 | Buy |
| MA 10 | $1.23 | Buy | $1.25 | Buy |
| MA 20 | $1.26 | Buy | $1.25 | Buy |
| MA 50 | $1.28 | Buy | $1.33 | Sell |
| MA 100 | $1.52 | Sell | $1.73 | Sell |
| MA 200 | $2.80 | Sell | $4.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.02 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 75.21 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 3.17 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 64.15 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.27 | Buy |
| ADX (14) | 7.62 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50.
SMA50 is $1.28 and SMA200 is $2.85, with support at $1.18 and resistance at $1.37.
The thirty-day range runs from $1.00 to $1.58, reflecting a tighter near-term trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $1.30 | $1.81 | 0% | Neutral | |
| $0.9633 | $1.25 | $1.73 | -4% | Neutral | |
| $1.23 | $1.65 | $2.38 | +27% | Bullish | |
| $1.31 | $1.82 | $2.72 | +40% | Bullish | |
| $1.21 | $1.72 | $2.66 | +33% | Bullish | |
| $1.23 | $1.79 | $2.83 | +38% | Bullish | |
| $1.07 | $1.60 | $2.58 | +23% | Bullish | |
| $1.07 | $1.63 | $2.69 | +25% | Bullish | |
| $1.23 | $1.92 | $3.23 | +48% | Bullish | |
| $1.28 | $2.04 | $3.50 | +57% | Bullish | |
| $1.29 | $2.25 | $4.15 | +73% | Bullish | |
| $2.24 | $4.63 | $9.46 | +256% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.14 | $1.30 | $1.52 | +0.00% |
| June 2026 | $1.08 | $1.27 | $1.55 | -2.01% |
| July 2026 | $1.13 | $1.35 | $1.67 | +5.88% |
| August 2026 | $1.14 | $1.37 | $1.72 | +1.77% |
| September 2026 | $1.11 | $1.35 | $1.70 | -1.83% |
| October 2026 | $1.14 | $1.39 | $1.78 | +3.46% |
| November 2026 | $1.18 | $1.45 | $1.86 | +3.72% |
| December 2026 | $1.13 | $1.40 | $1.81 | -3.51% |
Click any year to see its month-by-month DRMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dermata Therapeutics, Inc.'s 2026 outlook centres on $1.30, within a $1.14 to $1.81 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DRMA could reach as high as $1.73, with a base case around $1.25 and support toward $0.9633 — roughly -4% from $1.30. Price action looks broadly range-bound.
Expect DRMA to range from $1.23 to $2.38 through 2028. The $1.65 average target implies a +27% move from current prices. That is up +32% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The DRMA price prediction for 2029 points to an average of $1.82 (low $1.31, high $2.72) — a potential gain of +40% on today's $1.30. Momentum favours further upside here.
In 2030, DRMA is projected to trade between $1.21 and $2.66, averaging $1.72 — a potential gain of +33% from today's $1.30. That is -5% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Dermata Therapeutics, Inc.'s 2031 outlook centres on $1.79, within a $1.23 to $2.83 range. That is up +4% on the projected 2030 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2032, DRMA could reach as high as $2.58, with a base case around $1.60 and support toward $1.07 — roughly +23% from $1.30. Buyers look set to stay in control over this stretch.
Expect DRMA to range from $1.07 to $2.69 through 2033. The $1.63 average target implies a +25% move from current prices. That is up +2% on the projected 2032 average. Momentum favours further upside here.
The DRMA price prediction for 2034 points to an average of $1.92 (low $1.23, high $3.23) — a potential gain of +48% on today's $1.30. Buyers look set to stay in control over this stretch.
In 2035, DRMA is projected to trade between $1.28 and $3.50, averaging $2.04 — a potential gain of +57% from today's $1.30. That is up +7% on the projected 2034 average. Momentum favours further upside here.
Dermata Therapeutics, Inc.'s 2040 outlook centres on $2.25, within a $1.29 to $4.15 range. That is up +10% on the projected 2035 average. That marks a +73% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DRMA could reach as high as $9.46, with a base case around $4.63 and support toward $2.24 — roughly +256% from $1.30. Momentum favours further upside here.
Investing $1,000 in DRMA today (≈ 769.230769 DRMA) could be worth
$3,558.91
+$2,558.91 (+256%) by 2050 · US Dollar
Based on the average projected DRMA price of $4.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRMAwould be worth at today's price.
$1,000 invested in DRMA on May 27, 2025 (≈ 133.333333 DRMA) would be worth
$173.33
-$826.67 (-82.7%) today · 0.17× · US Dollar
Based on a DRMA entry price of $7.5 vs. today's $1.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.25 | $1,040 | +4.0% |
| 1 month ago | $1.21 | $1,074.38 | +7.4% |
| 3 months ago | $1.25 | $1,040 | +4.0% |
| 6 months ago | $3.14 | $414.01 | -58.6% |
| 1 year ago | $7.5 | $173.33 | -82.7% |
| All time (4.8y) ago | $12,456 | $0.1 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRMA forecast.
Our base-case forecast reaches $2.60 around 2050.
Implied market cap at $2.60: $10.46M
The multi-year forecast shows a bullish trajectory with meaningful upside potential. For 2030, the average price is $1.67 and the ROI is 32.5, with sentiment labeled BULLISH.
By 2040, the average price is $2.20 and the ROI is 74.4, still with a BULLISH sentiment, moving higher than earlier years.
By 2050, the average price is $4.44 and the ROI is 252.5, with a lasting BULLISH sentiment. The 2050 forecast also notes a max of $9.02.
Across the horizon, the forecast indicates continued bullish momentum, supported by rising average prices through 2050. Market volatility remains elevated, with annualized volatility at 70, highlighting substantial uncertainty and risk alongside potential upside.
Tap a question to reveal the answer.
The average forecast price for 2030 is $1.67, with a low of $1.18 and a high of $2.57. The forecasted ROI is 32.5 and sentiment is BULLISH.
Forecasts show bullish sentiment in multiple years, with 2030 average $1.67 (ROI 32.5), 2040 average $2.20 (ROI 74.4), and 2050 average $4.44 (ROI 252.5). Note that these are estimates and not guarantees.
Yes. The 2050 forecast max is $9.02, with the 2050 average at $4.44 and a bullish outlook.
The 30-day range is $1.00–$1.58. The current price is $1.26. RSI14 is 50, SMA50 is $1.28, SMA200 is $2.85, with support at $1.18 and resistance at $1.37.
Current price is $1.26 and market cap is $5.07M. The asset is ranked #5340.
Dermata Therapeutics, Inc. Community Discussion
0Share your Dermata Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.